FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912255887> ?p ?o ?g. }

• W2912255887 endingPage "1682" @default.
• W2912255887 startingPage "1682" @default.
• W2912255887 abstract "Abstract Introduction In Acute Myeloid Leukemia (AML) internal tandem duplications (ITD) in the fms-related tyrosine kinase 3 (FLT3) are a frequent event associated with an unfavorable prognosis. At diagnosis, the FLT3-ITD status is routinely assessed by fragment analysis of PCR-amplified cDNA. However, this assay only provides information on the length but not on the position and sequence of the insertion. Therefore, it is attractive to overcome this limitation by the use of high-throughput amplicon sequencing (HTAS) as an alternative strategy for FLT3-ITD detection. To proof the feasibility and accuracy of this approach we performed HTAS on 260 AML patients, of which 250 were FLT3-ITD positive according to routine diagnostics. Patients and Methods All samples were obtained from patients treated on the German Acute Myeloid Leukemia Cooperative Group (AMLCG) trials 1999, 2004 and 2008. All patients received intensive induction therapy with curative intent. At diagnosis, patients had a median age of 60 years (range, 18-80 years). Additional molecular marker were screened routinely: NPM1 mutation (62%), KMT2A-PTD (8%), CEBPA mutations (8%). According to the ELN-classification patients clustered into the following groups: ELN intermediate I (70%), intermediate II (21%) or adverse (9%). A normal karyotype was observed in 71%, while 29% had an aberrant karyotpye. All patient samples were analyzed routinely by FLT3 fragment analysis. For HTAS of FLT3 we used custom FLT3 cDNA primers including barcode and adapter-sequences enabling a one-step PCR-protocol. Sequencing was performed (2x250bp paired end) on a MiSeq (Illumina). Per run, up to 96 samples were sequenced, yielding a median of 79,110 reads per amplicon (range: 31,996 - 259,783). As controls, cDNA from FLT3-ITD positive (Molm-13) and negative (HL60) cell lines were used. Sequencing data were aligned to the FLT3 cDNA reference (NM_004119.2) and FLT3-ITDs were called using Pindel software (version 0.2.5a7). Results Based on the HTAS results obtained from the FLT3 wild-type control HL60, we set the cut-off for ITD detection at a variant allele frequency (VAF) of 0.5%. Using this threshold, all patients which were assessed to be FLT3-ITD negative in diagnostic routine, were also negative in HTAS. FLT3-ITDs were detected by HTAS in 242 out of 250 (97%) patients who were FLT3-ITD positive patients according to routine fragment analysis. For six out of the 8 remaining patients, no valid ITD was detected by HTAS possibly due to one of the following reasons: a low mutational burden resulting in a VAF below the cut-off level (n=4) or a deletion near the ITD (n=2) potentially interfering with ITD-detection. In total, 308 ITDs were detected in 242 patients by HTAS while in these patients 282 ITDs were detected by routine diagnostics. Of note, HTAS missed 13 subclonal ITDs reported in routine, while 39 additional subclonal ITDs were detected by HTAS only. Overall, HTAS detected a higher number of ITDs per patient (mean: 1.27; range: 1-4) compared to fragment analysis (mean: 1.17; range: 1-3). Patients with more than one ITD according to HTAS showed a trend towards shorter overall and relapse free survival (p=0.105, p=0.104 respectively; Figure 1A). The ITD position (i.e. affected FLT3 domain) based on HTAS did not impact on clinical outcome. There was a significant correlation between the FLT3-ITD levels detected by fragment analysis and HTAS (Pearson, R=0.801, p=0.01; Figure 1B). High FLT3-ITD levels measured by fragment analysis had a significant impact on RFS, whereas this effect was not observed for FLT3-ITD levels measured by HTAS. The quantification of FLT3-ITD by HTAS might be hampered by underestimation of the VAFs of long ITDs that are less likely to be mapped correctly compared to shorter ITDs. Conclusion In summary, our study demonstrates the feasibility of HTAS for FLT3-ITD detection in AML. In particular, the identification of subclonal ITDs with high sensitivity provides additional information with potential prognostic value. Thus, HTAS may serve as a robust tool that could be implemented in future diagnostic routines. However, bioinformatic algorithms for ITD detection may need further improvement, e.g. to optimize ITD quantification and to facilitate the detection of ITDs in combination with deletions. Disclosures Hiddemann: Roche: Other: Grants; Genentech: Other: Grants; Roche: Membership on an entity's Board of Directors or advisory committees." @default.
• W2912255887 created "2019-02-21" @default.
• W2912255887 creator A5010084276 @default.
• W2912255887 creator A5012020159 @default.
• W2912255887 creator A5022720568 @default.
• W2912255887 creator A5025105470 @default.
• W2912255887 creator A5026017495 @default.
• W2912255887 creator A5030808762 @default.
• W2912255887 creator A5033935778 @default.
• W2912255887 creator A5047397104 @default.
• W2912255887 creator A5051692996 @default.
• W2912255887 creator A5054595884 @default.
• W2912255887 creator A5056151840 @default.
• W2912255887 creator A5058099757 @default.
• W2912255887 creator A5060976490 @default.
• W2912255887 creator A5063547268 @default.
• W2912255887 creator A5065426246 @default.
• W2912255887 creator A5071091625 @default.
• W2912255887 creator A5072021108 @default.
• W2912255887 creator A5081560063 @default.
• W2912255887 date "2016-12-02" @default.
• W2912255887 modified "2023-09-27" @default.
• W2912255887 title "Comparison of FLT3-ITD Detection By High-Throughput Amplicon Sequencing to Routine Diagnostics - a Retrospective Analysis of AMLCG Study Patients" @default.
• W2912255887 doi "https://doi.org/10.1182/blood.v128.22.1682.1682" @default.
• W2912255887 hasPublicationYear "2016" @default.
• W2912255887 type Work @default.
• W2912255887 sameAs 2912255887 @default.
• W2912255887 citedByCount "0" @default.
• W2912255887 crossrefType "journal-article" @default.
• W2912255887 hasAuthorship W2912255887A5010084276 @default.
• W2912255887 hasAuthorship W2912255887A5012020159 @default.
• W2912255887 hasAuthorship W2912255887A5022720568 @default.
• W2912255887 hasAuthorship W2912255887A5025105470 @default.
• W2912255887 hasAuthorship W2912255887A5026017495 @default.
• W2912255887 hasAuthorship W2912255887A5030808762 @default.
• W2912255887 hasAuthorship W2912255887A5033935778 @default.
• W2912255887 hasAuthorship W2912255887A5047397104 @default.
• W2912255887 hasAuthorship W2912255887A5051692996 @default.
• W2912255887 hasAuthorship W2912255887A5054595884 @default.
• W2912255887 hasAuthorship W2912255887A5056151840 @default.
• W2912255887 hasAuthorship W2912255887A5058099757 @default.
• W2912255887 hasAuthorship W2912255887A5060976490 @default.
• W2912255887 hasAuthorship W2912255887A5063547268 @default.
• W2912255887 hasAuthorship W2912255887A5065426246 @default.
• W2912255887 hasAuthorship W2912255887A5071091625 @default.
• W2912255887 hasAuthorship W2912255887A5072021108 @default.
• W2912255887 hasAuthorship W2912255887A5081560063 @default.
• W2912255887 hasConcept C104317684 @default.
• W2912255887 hasConcept C126322002 @default.
• W2912255887 hasConcept C143998085 @default.
• W2912255887 hasConcept C2483381 @default.
• W2912255887 hasConcept C2778729363 @default.
• W2912255887 hasConcept C30481170 @default.
• W2912255887 hasConcept C45091340 @default.
• W2912255887 hasConcept C49105822 @default.
• W2912255887 hasConcept C501734568 @default.
• W2912255887 hasConcept C51679486 @default.
• W2912255887 hasConcept C53226629 @default.
• W2912255887 hasConcept C54355233 @default.
• W2912255887 hasConcept C71924100 @default.
• W2912255887 hasConcept C76818968 @default.
• W2912255887 hasConcept C8185291 @default.
• W2912255887 hasConcept C86803240 @default.
• W2912255887 hasConceptScore W2912255887C104317684 @default.
• W2912255887 hasConceptScore W2912255887C126322002 @default.
• W2912255887 hasConceptScore W2912255887C143998085 @default.
• W2912255887 hasConceptScore W2912255887C2483381 @default.
• W2912255887 hasConceptScore W2912255887C2778729363 @default.
• W2912255887 hasConceptScore W2912255887C30481170 @default.
• W2912255887 hasConceptScore W2912255887C45091340 @default.
• W2912255887 hasConceptScore W2912255887C49105822 @default.
• W2912255887 hasConceptScore W2912255887C501734568 @default.
• W2912255887 hasConceptScore W2912255887C51679486 @default.
• W2912255887 hasConceptScore W2912255887C53226629 @default.
• W2912255887 hasConceptScore W2912255887C54355233 @default.
• W2912255887 hasConceptScore W2912255887C71924100 @default.
• W2912255887 hasConceptScore W2912255887C76818968 @default.
• W2912255887 hasConceptScore W2912255887C8185291 @default.
• W2912255887 hasConceptScore W2912255887C86803240 @default.
• W2912255887 hasIssue "22" @default.
• W2912255887 hasLocation W29122558871 @default.
• W2912255887 hasOpenAccess W2912255887 @default.
• W2912255887 hasPrimaryLocation W29122558871 @default.
• W2912255887 hasRelatedWork W2091691053 @default.
• W2912255887 hasRelatedWork W2120607581 @default.
• W2912255887 hasRelatedWork W2531443719 @default.
• W2912255887 hasRelatedWork W2549717417 @default.
• W2912255887 hasRelatedWork W2587810752 @default.
• W2912255887 hasRelatedWork W2912255887 @default.
• W2912255887 hasRelatedWork W2979865820 @default.
• W2912255887 hasRelatedWork W2988053143 @default.
• W2912255887 hasRelatedWork W2993316876 @default.
• W2912255887 hasRelatedWork W3144861405 @default.
• W2912255887 hasVolume "128" @default.
• W2912255887 isParatext "false" @default.
• W2912255887 isRetracted "false" @default.
• W2912255887 magId "2912255887" @default.
• W2912255887 workType "article" @default.